MapLight Therapeutics (NASDAQ:MPLT) saw insider activity on May 11, 2026, as General Counsel Kristopher Hanson divested a portion of his holdings in the company's voting common stock. The total value of the shares sold amounted to $419,263. These transactions were not singular events but were comprised of several distinct sales at varying price points, ranging from a low of $27.61 to a high of $30.56 per share.
The disposal involved a total of 13,917 shares. A detailed breakdown of the individual transaction tranches reveals the following:
- First Tranche: 284 shares were sold at a weighted average price of $27.61, with prices per share fluctuating between $27.26 and $28.08.
- Second Tranche: 846 shares were traded at a weighted average price of $28.70, with individual transaction prices spanning from $28.30 to $29.183.
- Third Tranche: 6,979 shares were sold at a weighted average price of $30.04, with specific prices between $29.305 and $30.2965.
- Fourth Tranche: 5,808 shares were sold at a weighted average price of $30.56, with transactions occurring between $30.305 and $30.90.
Following the completion of these sales, Mr. Hanson retains a direct holding of 162,331 shares of MapLight Therapeutics voting common stock. It is noted that these trades were conducted pursuant to a Rule 10b5-1 trading plan, which had been adopted by Mr. Hanson on December 29, 2025.
Market Context and Clinical Milestones
The sale takes place against a backdrop of significant stock performance for MPLT. Over the last six months, the stock has seen a 108% surge, with current trading levels hovering around $30. This places the stock near its 52-week high of $33.28. While analysts at InvestingPro suggest the stock may appear overvalued at these current levels, the company is approaching critical clinical inflection points.
MapLight Therapeutics has recently reached significant milestones in its clinical development programs. The company has completed enrollment for its Phase 2 ZEPHYR trial, which focuses on schizophrenia, and has finalized patient visits for its Phase 2 IRIS trial, targeting autism spectrum disorder. Management anticipates that topline results from these trials will be released by mid-August 2026.
Analyst Perspectives
Financial institutions have maintained a positive outlook on the company's neuropsychiatric pipeline. TD Cowen recently initiated coverage with a buy rating, specifically highlighting the potential of the lead asset, ML-007C-MA. Stifel has also reiterated its Buy rating and held a price target of $28.00 following the company's fourth-quarter update. Stifel noted that the Phase 2 data readout for ML-007C-MA is expected in the third quarter of 2026, suggesting that the M1/M4 mechanism is de-risked by Cobenfy, though researchers are looking for confirmation of efficacy and potential differentiation regarding dosing, safety, or tolerability.